Obesity
HT-6184 is designed to address one of the root causes of obesity-related metabolic dysfunction
John’s* Day
SAMPLE DAILY EXPERIENCES WITH OBESITY
John faces a range of challenges that impact his physical and mental well-being. Every day, he experiences pain in his knees and hips and fatigue after minimal exertion, causing difficulty with mobility. Simple tasks like walking up stairs or standing for long periods are exhausting and painful.
Emotionally, John deals with stigma and discrimination fueling his low self-esteem, depression, and isolation. Social interaction is stressful, feeling self-conscious and fearing judgment from others.
Managing his diet and exercise is a significant challenge. Willingly or unwillingly, John needs to monitor his diet constantly. Some days, he doesn’t do so well, sending him into a spiral of depression. He has great difficulty maintaining exercise routines, and his failures are overwhelming.
Additionally, John has diabetes, requiring continuous medical management, adding another layer of complexity to his daily life.
What would John’s life be like without the daily struggle with obesity? Halia is focused on making the answer to that question a reality.
*Names and likenesses are changed to protect patient privacy.
I’m worried about my health and the stigma that comes with it. I just want to feel better and be able to live my life fully.
Obesity
Halia Therapeutics is pioneering a new approach to obesity treatment with HT-6184, a therapy that targets the NLRP3 inflammasome—a key driver of inflammation in metabolic diseases. By inhibiting NLRP3 activity, HT-6184 may reduce inflammation, addressing metabolic disturbances central to obesity, type 2 diabetes, and cardiovascular disease.
A key mechanism by which HT-6184 exerts its effects is through the modulation of macrophage polarization. In obesity, macrophages—immune cells crucial for maintaining tissue homeostasis—can exist in different states. These states are commonly referred to as M1 (pro-inflammatory) and M2 (anti-inflammatory) macrophages.17,18
By promoting a shift from the M1 pro-inflammatory state to the M2 anti-inflammatory state, HT-6184 could potentially reduce chronic inflammation associated with obesity, leading to improved metabolic outcomes, enhanced tissue repair, and overall better systemic health. This modulation of macrophage polarization may be particularly relevant in mitigating obesity-related comorbidities such as insulin resistance and cardiovascular disease.
Obesity
Almost half of US adults are obese or severely obese. Lack of physical activity, unhealthy eating behavior, and, in some cases, genetics contribute to obesity. Halia is developing investigational treatments to combat obesity.
Pain and Rheumatoid Arthritis
Rheumatoid Arthritis (RA) is an autoimmune condition where the immune system—normally the body's defender against infection and disease—attacks its own tissues. This results in pain, swelling, stiffness, and loss of joint function. Halia is developing an investigational treatment for both RA and post-surgical pain.
Alzheimer's Disease
Alzheimer’s disease involves parts of the brain that control memory, language, problem-solving, and other thinking abilities. It can seriously affect a person’s ability to carry out daily activities. Halia is developing a potentially relevant pathway and investigational treatment for Alzheimer’s.
Parkinson's Disease
Parkinson’s disease is a progressive disorder that affects the nervous system and the parts of the body controlled by the nerves. Tremors, stiffness, or slowing of movement are typical symptoms. Halia is developing a potential brain-penetrant compound to treat the disease.